The Year in Interventional Cardiology

Journal of the American College of Cardiology

Volumn 55, Issue 20, 2010, Pages 2272-2286

  Dixon, Simon R ^a   Grines, Cindy L ^a   O'Neill, William W ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

interventional; peripheral; stent; vascular

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ADENOSINE; ATORVASTATIN; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; ERYTHROPOIETIN; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; ILOPROST; IODIXANOL; IOXAGLIC ACID; PACLITAXEL; PIOGLITAZONE; PLACEBO; PRASUGREL; PRAVASTATIN; RAPAMYCIN; TENECTEPLASE; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; UNINDEXED DRUG; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AORTA BALLOON; AORTA VALVE STENOSIS; BALLOON DILATATION; BARE METAL STENT; BLEEDING; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; CARDIOGENIC SHOCK; CAROTID ARTERY STENTING; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG DOSE COMPARISON; DRUG ELUTING STENT; DRUG MEGADOSE; EVENT FREE SURVIVAL; FRACTIONAL FLOW RESERVE; HEART ATRIUM APPENDAGE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEMATOPOIETIC STEM CELL; HUMAN; IN-STENT RESTENOSIS; INTRACORONARY INFUSION; KIDNEY ARTERY STENOSIS; KIDNEY INNERVATION; LOADING DRUG DOSE; MITRAL VALVE REGURGITATION; OPTIMAL DRUG DOSE; PATENT FORAMEN OVALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBUS ASPIRATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADENOSINE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS AS TOPIC; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY OCCLUSION; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FORAMEN OVALE, PATENT; HOSPITAL MORTALITY; HUMANS; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RADIOLOGY, INTERVENTIONAL; RECEPTORS, PURINERGIC P2; THIOPHENES; THROMBOLYTIC THERAPY; TICLOPIDINE; TREATMENT OUTCOME;

EID: 77951948636     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.02.024     Document Type: Review

References (180)

1. Kushner F.G., Hand M., Smith Jr. S.C., et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120 (2009) 2271-2306
2. Huynh T., Perron S., O'Loughlin J., et al. Comparison of primary percutaneous coronary intervention and fibrinolytic therapy in ST-segment-elevation myocardial infarction. Bayesian hierarchical meta-analyses of randomized controlled trials and observational studies. Circulation 119 (2009) 3101-3109
3. Cantor W.J., Fitchett D., Borgundvaag B., et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 360 (2009) 2705-2718
4. Bohmer E., Hoffmann P., Abdelnoor M., et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances. Results of the NORDISTEMI (NORwegian study on District treatment of ST-Elevation Myocardial Infarction). J Am Coll Cardiol 55 (2010) 102-110
5. Carver A., Rafelt S., Gershlick A.H., et al. Longer-term follow-up of patients recruited to the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) trial. J Am Coll Cardiol 54 (2009) 118-126
6. Ellis S.G., Tendera M., de Belder M.A., et al. 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events) trial. J Am Coll Cardiol Intv 2 (2009) 909-916
7. Herrmann H.C., Lu J., Brodie B.R., et al. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. J Am Coll Cardiol Intv 2 (2009) 917-924
8. Brar S.S., Leon M.B., Stone G.W., et al. Use of drug-eluting stents in acute myocardial infarction. A systematic review and meta-analysis. J Am Coll Cardiol 53 (2009) 1677-1689
9. Di Lorenzo E., Sauro R., Varricchio A., et al. Long-term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction. Circulation 120 (2009) 964-972
10. Di Lorenzo E., De Luca G., Sauro R., et al. The PASEO (Paclitaxel or sirolimus-eluting stent versus bare metal stent in primary angioplasty) randomized trial. J Am Coll Cardiol Intv 2 (2009) 515-523
11. Stone G.W., Lansky A.J., Pocock S.J., et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 360 (2009) 1946-1959
12. Stone GW. HORIZONS AMI. Two-year follow-up from a prospective, randomized trial of heparin plus glycoprotein IIb/IIIa inhibitors vs. bivalirudin and paclitaxel-eluting vs. bare metal stents in STEMI. Paper presented at: Transcatheter Cardiovascular Therapeutics 2009; September 25, 2009; San Francisco, CA.
13. Tebaldi M., Arcozzi C., Campo G., et al. The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 20 (2009) 1900-1901
14. Michels R. DEBATER. A comparison of drug-eluting stents and bare metal stents with or without abciximab in ST-segment elevation myocardial infarction. The Eindhoven reperfusion study. Paper presented at: Transcatheter Cardiovascular Therapeutics 2009; September 25, 2009; San Francisco, CA.
15. Cervinka P, Bystron M, Spacek R, et al. Randomized comparison of Genous stent versus chromium-cobalt stent for treatment of ST-elevation myocardial infarction. 6-month clinical, angiographic and IVUS follow-up (GENIUS-STEMI). Paper presented at: American College of Cardiology; March 28, 2009; Orlando, FL.
16. Sardella G., Mancone M., Bucciarelli-Ducci C., et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size. J Am Coll Cardiol 53 (2009) 309-315
17. Liistro F., Grotti S., Angioli P., et al. Impact of thrombus aspiration on myocardial tissue reperfusion and left ventricular functional recovery and remodeling after primary angioplasty. Circ Cardiovasc Intervent 2 (2009) 376-383
18. Haeck J.D.E., Koch K.T., Bilodeau L., et al. Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (Proximal embolic protection in acute myocardial infarction and resolution of ST-elevation study). J Am Coll Cardiol Intv 2 (2009) 934-943
19. Stone G.W., Martin J.L., de Boer M., et al. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Intervent 2 (2009) 366-375
20. Sezer M., Cimen A., Aslanger E., et al. Effect of intracoronary streptokinase administered immediately after primary percutaneous coronary intervention on long-term left ventricular infarct size, volumes, and function. J Am Coll Cardiol 54 (2009) 1065-1071
21. Ott I, Schulz S, Mehilli J, et al. Prospective, randomized, double-blind, placebo-controlled trial of erythropoietin in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (REVIVAL-3). Paper presented at: American College of Cardiology; March 30, 2009; Orlando, FL.
22. Fokkema M.L., Vlaar P.J., Vogelzang M., et al. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction. A randomized controlled trial. Circ Cardiovasc Intervent 2 (2009) 323-329
23. Atar D., Petzelbauer P., Schwitter J., et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 53 (2009) 720-729
24. Nikolsky E., Mehran R., Sadeghi M., et al. Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and device investigation to lower late angioplasty complications) trial. J Am Coll Cardiol Intv 2 (2009) 624-632
25. Jolicoeur E.M., O'Neill W.W., Hellkamp A., et al. Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J 30 (2009) 2575-2583
26. Shishehbor M.H., Madhwal S., Rajagopal V., et al. Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol Intv 2 (2009) 46-53
27. Srinivas V.S., Hailpern S.M., Koss E., et al. Effect of physician volume on the relationship between hospital volume and mortality during primary angioplasty. J Am Coll Cardiol 53 (2009) 574-579
28. Kumbhani D.J., Cannon C.P., Fonarow G.C., et al. Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes. JAMA 302 (2009) 2207-2213
29. Lim H.S., Farouque O., Andrianopoulos N., et al. Survival of elderly patients undergoing percutaneous coronary intervention for acute myocardial infarction complicated by cardiogenic shock. J Am Coll Cardiol Intv 2 (2009) 146-152
30. Mehta R., Ou F.S., Peterson E.D., et al. Clinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention. J Am Coll Cardiol Intv 2 (2009) 56-64
31. + very small embryonic-like stem cells in patients with acute myocardial infarction. J Am Coll Cardiol 53 (2009) 1-9
32. Herbots L., D'hooge J., Eroglu E., et al. Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study. Eur Heart J 30 (2009) 662-670
33. Tendera M., Wojakowski W., Ruzyllo W., et al. Intracoronary infusion of bone marrow-derived selected CD34+ CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre myocardial regeneration by intracoronary infusion of selected population of stem cells in acute myocardial infarction (REGENT) trial. Eur Heart J 30 (2009) 1313-1321
34. Yousef M., Schannwell C., Köstering M., et al. Clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol 53 (2009) 2262-2269
35. Mehta S.R., Granger C.B., Boden W.E., et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 360 (2009) 2165-2175
36. Montalescot G., Cayla G., Collet J.P., et al. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA 302 (2009) 947-954
37. Giugliano R.P., White J.A., Bode C., et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360 (2009) 2176-2190
38. Nikolsky E., Stone G.W., Kirtane A.J., et al. Gastrointestinal bleeding in patients with acute coronary syndromes; incidence, predictors, and clinical implications. J Am Coll Cardiol 54 (2009) 1293-1302
39. Mehran R., Nikolsky E., Lansky A.J., et al. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute catheterization and urgent intervention triage strategy) substudy. J Am Coll Cardiol Intv 2 (2009) 748-757
40. Lopes R.D., Alexander K.P., Manoukian S.V., et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 53 (2009) 1021-1030
41. Prasad A., Gersh B.J., Bertrand M.E., et al. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes. J Am Coll Cardiol 54 (2009) 477-486
42. Patel M.R., Dehmer G.J., Hirshfeld J.W., et al. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 appropriateness criteria for coronary revascularization: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society of Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology. Circulation 119 (2009) 1330-1352
43. The BARI 2D study group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360 (2009) 2503-2515
44. Trikalinos T.A., Alsheikh-Ali A.A., Tatsioni A., et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 373 (2009) 911-918
45. Thiele H., Neumann-Schniedewind P., Jacobs S., et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol 53 (2009) 2324-2331
46. Serruys P.W., Morice M.C., Kappetein A.P., et al. Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. N Engl J Med 360 (2009) 961-972
47. Li Y., Zheng Z., Xu B., et al. Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: three-year follow-up results from a single institution. Circulation 119 (2009) 2040-2050
48. Hlatky M.A., Boothroyd D.B., Bravata D.M., et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomized trials. Lancet 373 (2009) 1190-1197
49. Buszman P.E., Buszman P.P., Kiesz R.S., et al. Early and long-term results of unprotected left main coronary artery stenting. The LE MANS (left main coronary artery stenting) registry. J Am Coll Cardiol 54 (2009) 1500-1511
50. Kim Y.H., Park D.W., Lee S.W., et al. Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents. Circulation 120 (2009) 400-407
51. Toyofuku M., Kimura T., Morimoto T., et al. Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the J-Cypher registry. Circulation 120 (2009) 1866-1874
52. Vaquerizo B., Lefèvre T., Darremont O., et al. Unprotected left main stenting in the real world: two-year outcomes of the French left main Taxus registry. Circulation 119 (2009) 2349-2356
53. Lee J.Y., Park D.W., Yun S.C., et al. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease. J Am Coll Cardiol 54 (2009) 853-859
54. Mehilli J., Kastrati A., Byrne R.A., et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 53 (2009) 1760-1768
55. Park S.J., Kim Y.H., Park D.W., et al. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. Circ Cardiovasc Intervent 2 (2009) 167-177
56. Sheiban I., Sillano D., Biondi-Zoccai G., et al. Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents. J Am Coll Cardiol 54 (2009) 1131-1136
57. Palmerini T., Marzocchi A., Tamburino C., et al. Temporal pattern of ischemic events in relation to dual antiplatelet therapy in patients with unprotected left main coronary artery stenosis undergoing percutaneous coronary intervention. J Am Coll Cardiol 53 (2009) 1176-1181
58. Tonino P.A.L., De Bruyne B., Pijls N.H.J., et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360 (2009) 213-224
59. Redwood S. Balloon-pump assisted Coronary Intervention Study (BCIS-1). Paper presented at: Transcatheter Cardiovascular Therapeutics 2009; September 25, 2009; San Francisco, CA.
60. Dixon S.R., Henriques J.P.S., Mauri L., et al. A prospective feasibility trial investigating the use of the Impella 2.5 in patients undergoing high-risk percutaneous coronary intervention (the PROTECT I trial): initial US experience. J Am Coll Cardiol Intv 2 (2009) 91-96
61. Sjauw K.D., Konorza T., Erbel R., et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device. The Europella Registry. J Am Coll Cardiol 54 (2009) 2430-2434
62. Colombo A., Bramucci E., Saccà, et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations. Circulation 119 (2009) 71-78
63. Katritsis D.G., Siontis G.C.M., and Ioannidis J.P.A. Double versus single stenting for coronary bifurcation lesions. A meta-analysis. Circ Cardiovasc Intervent 2 (2009) 409-415
64. Niemela M. A prospective randomized trial of side branch dilatation strategies in patients with coronary bifurcation lesions undergoing treatment with a single stent (Nordic-Baltic Bifurcation Study III). Paper presented at: Transcatheter Cardiovascular Therapeutics 2009; September 25, 2009; San Francisco, CA.
65. Erglis A., Kumsars I., Niemela, et al. Randomized comparison of coronary bifurcation stenting with the crush versus culotte technique using sirolimus eluting stents: the Nordic stent technique study. Circ Cardiovasc Intervent 2 (2009) 27-34
66. Verheye S., Agostoni P., Dubois C.L., et al. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions. J Am Coll Cardiol 53 (2009) 1031-1039
67. Rathore S., Matsuo H., Terashima M., et al. Procedural and in-hospital outcomes after percutaneous coronary intervention for chronic total occlusion of coronary arteries 2002 to 2008: impact of novel guidewire techniques. J Am Coll Cardiol Intv 2 (2009) 489-497
68. Rathore S., Katoh O., Matsuo H., et al. Retrograde percutaneous recanalization of chronic total occlusion of the coronary arteries. Circ Cardiovasc Intervent 2 (2009) 124-132
69. Resnic F.S., and Welt F.G.P. The public health hazards of risk avoidance associated with public reporting of risk-adjusted outcomes in coronary intervention. J Am Coll Cardiol 53 (2009) 825-830
70. Khattab A.A., Hamm C.W., Senges J., et al. Sirolimus-eluting stent treatment at high-volume centers confers lower mortality at 6-month follow-up. Circulation 120 (2009) 600-606
71. Hannan E.L., Samadashvili Z., Walford G., et al. Predictors and outcomes of ad hoc versus non-ad hoc percutaneous coronary interventions. J Am Coll Cardiol Intv 2 (2009) 350-356
72. Ryan J., Linde-Zwirble W., Engelhart L., et al. Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program. Circulation 119 (2009) 952-961
73. van Ramhorst J., Bax J.J., Beeres S.L., et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 301 (2009) 1997-2004
74. Alfonso F., Pérez-Vizcayno M.P., Ruiz M., et al. Coronary aneurysms after drug-eluting stent implantation. Clinical, angiographic, and intravascular ultrasound findings. J Am Coll Cardiol 53 (2009) 2053-2060
75. Gonzalo N., Barlis P., Serruys P.W., et al. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography. J Am Coll Cardiol Intv 2 (2009) 445-452
76. Awata M., Nanto S., Uematsu M., et al. Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents. J Am Coll Cardiol Intv 2 (2009) 453-458
77. Kim J.W., Seo H.S., Park J.H., et al. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent. J Am Coll Cardiol 53 (2009) 1653-1659
78. Nakazawa G., Finn A.V., Vorpahl M., et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery. A pathologic analysis. J Am Coll Cardiol 54 (2009) 1924-1931
79. Eisenberg M.J., Richard P.R., Libersan D., and Filion K.B. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 119 (2009) 1634-1642
80. Kimura T., Morimoto T., Nakagawa Y., et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 119 (2009) 987-995
81. Lasala J.M., Cox D.A., Dobies D., et al. Drug eluting stent thrombosis in routine clinical practice. Circ Cardiovasc Intervent 2 (2009) 285-293
82. van Werkum J.W., Heestermans A.A., Zomer A.C., et al. Predictors of coronary stent thrombosis. The Dutch Stent Thrombosis Registry. J Am Coll Cardiol 53 (2009) 1399-1409
83. van Werkum J.W., Heestermans A.A.C.M., de Korte F.I., et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis. An analysis of 431 cases. Circulation 119 (2009) 828-834
84. Aoki J., Lansky A.J., Mehran R., et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents. Circulation 119 (2009) 687-698
85. Sibbing D., Braun S., Morath T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53 (2009) 849-856
86. Caixeta A., Leon M.B., Lansky A.J., et al. 5-year clinical outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol 54 (2009) 894-902
87. Weisz G., Leon M.B., Holmes D.R., et al. Five-year follow-up after sirolimus-eluting stent implantation. J Am Coll Cardiol 53 (2009) 1488-1497
88. Silber S., Colombo A., Banning A.P., et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based Paclitaxel-eluting stents for de novo coronary lesions. Circulation 120 (2009) 1498-1504
89. James S.K., Stenestrand U., Lindbäck J., et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 360 (2009) 1933-1945
90. Kirtane A.J., Gupta A., Iyengar S., et al. Safety and efficacy of drug-eluting and bare metal stents. Comprehensive meta-analysis of randomized trials and observational studies. Circulation 119 (2009) 3198-3206
91. Kaltoft A., Jensen L., Maeng M., et al. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare metal coronary stents. J Am Coll Cardiol 53 (2009) 658-664
92. Stone G.W., Midei M., Newman W., et al. Two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation 119 (2009) 680-688
93. Stone G. A prospective, randomized trial comparing an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease (SPIRIT IV). Paper presented at: Transcatheter Cardiovascular Therapeutics 2009; September 23, 2009; San Francisco, CA.
94. Smits P. COMPARE: a prospective randomized trial of everolimus-eluting versus paclitaxel-eluting stents. Paper presented at: Transcatheter Cardiovascular Therapeutics 2009; September 23, 2009; San Francisco, CA.
95. Park SJ. Comparison of the efficacy and safety of zotarolimus-eluting stent versus sirolimus-eluting stent and paclitaxel-eluting stent for coronary lesions (The ZEST trial). Paper presented at: American College of Cardiology; March 29, 2009; Orlando, FL.
96. Brilakis E.S., Lichtenwalter C., et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions. J Am Coll Cardiol 53 (2009) 919-928
97. Rodés-Cabau J., Bertrand O.F., Larose E., et al. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the moderate vein graft lesion stenting with the Taxus stent and intravascular ultrasound (VELETI) pilot trial. Circulation 2 (2009) 1978-1986 120
98. Kandzari D.E., Rao S.V., Moses J.W., et al. Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to chronic occlusions with sirolimus-eluting stents/total occlusion study of coronary arteries-4) trial. J Am Coll Cardiol Intv 2 (2009) 97-106
99. Carlsson J., James S.K., Lindbäck J., et al. Outcome of drug-eluting versus bare-metal stenting used according to on- and off-label criteria. J Am Coll Cardiol 53 (2009) 1389-1398
100. Ko D.T., Chiu M., Guo H., et al. Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications. J Am Coll Cardiol 53 (2009) 1773-1782
101. Mahmud E., Ormiston J.A., Turco M.A., et al. TAXUS Liberté attenuates the risk of restenosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS program. J Am Coll Cardiol Intv 2 (2009) 240-252
102. Fröbert O., Lagerqvist B., Carlsson J., et al. Difference in restenosis rate with difference drug-eluting stents in patients with and without diabetes mellitus. J Am Coll Cardiol 53 (2009) 1660-1667
103. Kirtane A.J., Patel R., O'Shaughnessy C., et al. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol Intv 2 (2009) 967-976
104. Popma J.J., Mauri L., O'Shaughnessy C., et al. Frequency and clinical consequences associated with sidebranch occlusion during stent implantation using zotarolimus-eluting and paclitaxel-eluting coronary stents. Circ Cardiovasc Intervent 2 (2009) 133-139
105. Byrne RA. Prospective, randomized trial of paclitaxel-versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents (ISAR DESIRE-2). Paper presented at: Transcatheter Cardiovascular Therapeutics 2009; September 23, 2009; San Francisco, CA.
106. Unverdorben M., Vallbracht C., Cremers B., et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary instent restenosis. Circulation 119 (2009) 2986-2994
107. Herdeg C., Göhring-Frischholz K., Haase K.K., et al. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation. Circ Cardiovasc Intervent 2 (2009) 294-301
108. In: Hamm C.W. (Ed). Paclitaxel-eluting PTCA-balloon in combination with the Coroflex Blue stent vs the sirolimus coated Cypher stent in the treatment of advanced coronary artery disease (PEPCAD III) (November 14, 2009), American Heart Association, Orlando, FL Paper presented
109. Ormiston J.A., Webster M.W.I., Schwartz R.S., et al. Feasibility, safety and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic status. J Am Coll Cardiol Intv 2 (2009) 1017-1024
110. Verheye S., Agostoni P., Dawkins K.D., et al. The GENESIS (randomized, multicenter study of the pimecrolimus-eluting and pimecrolimus/paclitaxel-eluting coronary stent system in patients with de novo lesions of the native coronary arteries) trial. J Am Coll Cardiol Intv 2 (2009) 205-214
111. Chevalier B., Silber S., Park S.J., et al. Randomized comparison of the Nobori biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries. Circ Cardiovasc Intervent 2 (2009) 188-195
112. Byrne R.A., Mehilli J., Iijima R., et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 30 (2009) 923-931
113. Han Y., Jing Q., Xu B., et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. J Am Coll Cardiol Intv 2 (2009) 303-309
114. Moore P., Berlis P., Spiro J., et al. A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents. J Am Coll Cardiol 2 (2009) 437-444
115. Byrne R.A., Kastrati A., Kufner S., et al. Randomized, non-inferiority trial of 3 limus agent-eluting stents with different polymer coatings (ISAR-TEST 4). Eur Heart J 20 (2009) 2441-2449
116. Costa J.R., Abizaid A., Costa R., et al. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. J Am Coll Cardiol Intv 2 (2009) 422-427
117. Tamburino C., Manna A., Elena M., et al. First-in-man 1-year clinical outcomes of the Catania coronary stent system with nanothin polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of the latest non-thrombogenic angioplasty stent) trial. J Am Coll Cardiol 2 (2009) 197-204
118. Serruys P.W., Ormiston J.A., Onuma Y., et al. A Bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373 (2009) 897-910
119. Waksman R., Erbel R., Di Mario C., et al. Early and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. J Am Coll Cardiol Intv 2 (2009) 312-320
120. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009) 345-362
121. Shuldiner A.R., O'Connell J.R., Bliden K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302 (2009) 849-857
122. Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360 (2009) 363-375
123. Cuisset T., Frere C., Quilici J., et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. J Am Coll Cardiol 54 (2009) 1149-1153
124. Ho P.M., Maddox T.M., Wang L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301 (2009) 937-944
125. O'Donoghue M.L., Braunwald E., Antman E.M., et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet 374 (2009) 989-997
126. Bhatt DL. The COGENT trial. Paper presented at Transcatheter Cardiovascular Therapeutics 2009; September 24, 2009; San Francisco, CA.
127. Gurbel P.A., Bliden K.P., Saucedo J.F., et al. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thromboelastographic indexes, and their relation to periprocedural infarction. J Am Coll Cardiol 53 (2009) 648-657
128. Valgimigli M., Campo G., de Cesare N., et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention. Circulation 119 (2009) 3215-3222
129. Dangas G., Mehran R., Guagliumi G., et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. J Am Coll Cardiol 54 (2009) 1438-1446
130. Mehta SR. CURRENT-STEMI PCI: double-dose vs standard-dose clopidogrel in ACS patients undergoing PCI for STEMI. Paper presented at: Transcatheter Cardiovascular Therapeutics 2009; September 24, 2009; San Francisco, CA.
131. Ebrahimi R., Dyke C., Mehran R., et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 53 (2009) 1965-1972
132. Montalesoct G., Wiviott S.D., Braunwald E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial. Lancet 373 (2009) 723-731
133. O'Donoghue M., Antman E., Braunwald E., et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention. J Am Coll Cardiol 54 (2009) 678-685
134. Morrow D.A., Wiviott S.D., White H.D., et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 119 (2009) 2758-2764
135. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009) 1045-1057
136. Steg G. PLATO STEMI. Outcomes in patients with STEMI and planned PCI. Paper presented at: American Heart Association; November 15, 2009; Orlando, FL.
137. Cannon C. PLATO Invasive. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes-the PLATelet Inhibition and patient Outcomes trial. Paper presented at: Transcatheter Cardiovascular Therapeutics 2009; September 24, 2009; San Francisco, CA.
138. Bhatt D., Lincoff A.M., Gibson C.M., et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361 (2009) 2330-2341
139. Harrington R., Stone G.W., McNulty S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361 (2009) 2318-2329
140. Jeong Y.H., Lee S.W., Choi B.R., et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity. J Am Coll Cardiol 53 (2009) 1101-1109
141. Chen K.Y., Rha S.W., Li Y.J., et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 119 (2009) 3207-3214
142. Gurm H.S., Tamhane U., Meier P., et al. A comparison of abciximab and small-molecule glycoprotein IIb/III inhibitors in patients undergoing primary percutaneous coronary intervention. A meta-analysis of contemporary randomized controlled trials. Circ Cardiovasc Intervent 2 (2009) 230-236
143. De Luca G., Ucci G., Cassetti E., and Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty. A meta-analysis. J Am Coll Cardiol 53 (2009) 1668-1673
144. Bonnefoy E. Comparison of pre-hospital or cath lab administration of high dose tirofiban in patients undergoing primary angioplasty. The AGIR2 study. Paper presented at: American College of Cardiology; March 29, 2009; Orlando, FL.
145. Le May M.R., Wells G.A., Glover C.A., et al. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction (ASSIST). Circ Cardiovasc Intervent 2 (2009) 330-338
146. Hamm CW. Ongoing Tirofiban in Myocardial Infarction Evaluation (ONTIME). Paper presented at: American College of Cardiology; March 29, 2009; Orlando, FL.
147. Mehilli J., Kastrati A., Schulz S., et al. Abciximab in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119 (2009) 1933-1940
148. Fung A.Y., Saw J., Starovoytov A., et al. Abbreviated infusion of eptifibatide after successful coronary intervention. J Am Coll Cardiol 53 (2009) 837-845
149. Becker R.C., Moliterno D.J., Jennings L.K., et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled phase II study. Lancet 373 (2009) 919-928
150. Mehran R., Lansky A., Witzenbichler B., et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomized controlled trial. Lancet 374 (2009) 1149-1159
151. Montalescot G., Gallo R., White H.D., et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention: 1-year results from the STEEPLE (Safety and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. J Am Coll Cardiol Intv 2 (2009) 1083-1091
152. Briguori C., Visconti G., Focaccio A., et al. Novel approaches for preventing or limiting events (Naples II) trial. J Am Coll Cardiol 54 (2009) 2157-2163
153. Di Sciascio G., Patti G., Pasceri V., et al. Efficacy of atorvastatin reload in patients in chronic statin therapy undergoing percutaneous coronary intervention. J Am Coll Cardiol 54 (2009) 558-565
154. Gibson C.M., Pride Y.B., Hochberg C.P., et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. J Am Coll Cardiol 54 (2009) 2290-2295
155. Takagi T., Okura H., Kobayashi Y., et al. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of in-stent neointimal proliferation by pioglitazone study). J Am Coll Cardiol Intv 2 (2009) 524-531
156. Jabara R., Gadesam R.R., Pendyala L.K., et al. Impact of the definition on the rate of contrast-induced nephropathy in percutaneous coronary intervention. Am J Cardiol 103 (2009) 1657-1662
157. Brown J.R., Block C.A., Malenka D.J., et al. Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. J Am Coll Cardiol Intv 2 (2009) 1116-1124
158. Spargias K., Adreanides E., Demerouti E., et al. Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 120 (2009) 1793-1799
159. Mehran R., Nikolsky E., Kirtane A.J., et al. Ionic low-osmolar versus iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic contrast to obviate worsening nephropathy after angioplasty in chronic renal failure patients) study. J Am Coll Cardiol Intv 2 (2009) 415-421
160. Wessely R., Koppara T., Bradaric C., et al. Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention. Circ Cardiovasc Intervent 2 (2009) 430-437
161. Reed M., Meier P., Tamhane U.U., et al. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. J Am Coll Cardiol Intv 2 (2009) 645-654
162. Krum H., Schlaich M., Whitbourn R., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373 (2009) 1275-1281
163. The ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361 (2009) 1953-1962
164. Gray W.A., Chaturvedi S., Verta P., et al. Thirty-day outcomes for carotid artery stenting in 6320 patients from 2 prospective, multicenter, high-surgical-risk registries. Circ Cardiovasc Intervent 2 (2009) 159-166
165. Chiam P.T.L., Roubin G.S., Panagopoulos S., et al. One-year clinical outcomes, midterm survival, and predictors of mortality after carotid stenting in elderly patients. Circulation 119 (2009) 2343-2348
166. Kasapis C., Henke P.K., Chetcuti S.J., et al. Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials. Eur Heart J 30 (2009) 44-45
167. Clavel M.A., Webb J.G., Pibarot P., et al. Comparison of the hemodynamic performance of percutaneous and surgical bioprostheses for the treatment of severe aortic stenosis. J Am Coll Cardiol 53 (2009) 1883-1891
168. Himbert D., Descoutures F., Al-Attar N., et al. Results of transfemoral or transapical aortic valve implantation following a uniform assessment in high-risk patients with aortic stenosis. J Am Coll Cardiol 54 (2009) 303-311
169. Webb J.G., Altwegg L., Boone R.H., et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation 119 (2009) 3009-3016
170. Webb J.G., Altwegg L., Masson J.B., et al. A new transcatheter aortic valve and percutaneous valve delivery system. J Am Coll Cardiol 53 (2009) 1855-1858
171. Détaint D., Lepage L., Himbert D., et al. Determinants of significant paravalvular regurgitation after transcatheter aortic valve implantation: impact of device and annulus discongruence. J Am Coll Cardiol Intv 2 (2009) 821-827
172. Feldman T., Kar S., Rinaldi M., et al. Percutaneous mitral repair with the MitraClip system. J Am Coll Cardiol 54 (2009) 686-694
173. Sack S., Kahlert P., Bilodeau L., et al. Percutaneous transvenous mitral annuloplasty. Initial human experience with a novel coronary sinus implant device. Circ Cardiovasc Intervent 2 (2009) 277-284
174. Schofer J., Siminiak T., Haude M., et al. Percutaneous mitral annuloplasty for functional mitral regurgitation. Results of the CARILLON mitral annuloplasty device European Union study. Circulation 120 (2009) 326-333
175. Holmes D.R., Reddy V.Y., Turi Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet 374 (2009) 534-542
176. Block P.C., Burstein S., Casale P.N., et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) study. J Am Coll Cardiol Intv 2 (2009) 594-600
177. Ford M.A., Reeder G.S., Lennon R.J., et al. Percutaneous device closure of patent foramen ovale in patients with presumed cryptogenic stroke or transient ischemic attack: the Mayo Clinic experience. J Am Coll Cardiol Intv 2 (2009) 404-411
178. Wahl A., Tai T., Praz F., et al. Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the Amplatzer PFO occluder without intraprocedural echocardiography: effect of device size. J Am Coll Cardiol Intv 2 (2009) 116-123
179. O'Gara P.T., Messe S.R., Tuzcu E.M., et al. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials: a science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. Circulation 119 (2009) 2743-2747
180. Vigna C., Marchese N., Inchingolo V., et al. Improvement of migraine after patent foramen percutaneous closure in patients with subclinical brain lesions: a case-control study. J Am Coll Cardiol Intv 2 (2009) 107-113